PD-1 Monoclonal Antibody Plus Apatinib Combined With SBRT in HCC With PVTT

Sponsor
Huazhong University of Science and Technology
Study ID
NCT04165174
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

It is a trial to assess the efficacy and safety of PD-1 monoclonal antibody plus Apatinib combined with SBRT as first-line treatment in HCC with PVTT.

Key Dates

Start date
Dec 31, 2019
Status verified
Nov 2019
Primary completion
Nov 30, 2020
Completion
Dec 31, 2020

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: PAS
    PD-1:240mg,ivdrip,Q3W,begin with SBRT Apatinib:250mg,po,QD,begin with SBRT SBRT:6-10Gy/F,5-8F

Primary Outcome Measure

PFS [ Time Frame: up to 3 years ]

Central Contacts

Related Studies